在人口规模的多维分析中,凝血因子XII的哈普洛因不足对静脉血栓栓塞有保护作用
Amelia K Haj1,2,3, David S Paul4,5, Sean J Jurgens2,6,7
1Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Nature communications
|September 1, 2025
概括
凝血因子XII (F12) 的基因变异可以防止静脉血栓塞栓,但不会增加出血风险. 这表明抑制XII因子可能是安全有效的治疗策略.
科学领域:
- 遗传学
- 血液静止
- 药理学
背景情况:
- 凝血因子XII (F12) 是预防血栓形成的潜在药物标.
- 支持F12定向治疗的人类数据有限.
- 研究F12在静脉血栓塞栓症 (VTE) 中的作用至关重要.
研究的目的:
- 使用人类遗传数据评估F12在静脉血栓塞的作用.
- 评估F12变种在出血和感染方面的安全性.
- 探索F12缺乏症的机理基础.
主要方法:
- 来自英国生物库和NIH All of Us的703,745名参与者的F12位点遗传变异分析.
- F12 变种载体的表型特征,包括出血,感染和 F12 水平.
- 在体外生成血栓的测试.
- 对F12异合体小鼠进行VTE保护模型的评估.
主要成果:
- 对F12变异的异构携带者 (无意义,位移动,拼接部位) 显示出对VTE的保护.
- 在F12变异携带者中没有发现出血或感染的风险增加.
- F12变异携带者表现出定量 (I型) 的F12缺陷,有些人表现出定性 (II型) 的缺陷.
- 在载体中与F12水平相关的体内血栓生成减少.
- 保护F12异构小鼠免受VTE的侵害.
结论:
- 对F12功能的异构损失提供了对VTE的保护.
- 这种脱状态表明F12抑制是一种潜在的安全和有效的治疗方法.
- 针对F12需要进一步研究以预防血栓形成.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
34
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
34
Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K


